United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting

SILVER SPRING, Md., & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced two presentations at the upcoming CHEST 2025 Annual Meeting hosted by the American College of Chest Physicians taking place October 19-22, 2025, in Chicago. In addition, United Therapeutics will sponsor and host several events including the PHinding Pulmonary Hypertension: Exploring Best Practices in PH-ILD Detection and Management dinner symposium and the Women in Chest Medicine Annual Luncheon.

“CHEST is a powerful platform for United Therapeutics and the pulmonary hypertension community to connect, share new developments, and elevate patient care,” said Andrew Nelsen, PharmD, VP of Global Medical Affairs. “We’re excited to sponsor the ‘PHinding Pulmonary Hypertension’ symposium and showcase rapid-fire presentations, including real-world data on earlier inhaled treprostinil use and its impact on hospitalization rates, plus new insights from the PHINDER study to refine screening for PH-ILD.”

Oral Presentations include:

Rapid fire original investigation presentation, Tuesday, October 21, 10:44 a.m. to 10:48 a.m. CDT: Rapid Area 4D/4075 – Echocardiographic Features of Patients with Pulmonary Hypertension Associated with Interstitial Lung: Interim Analysis of the PHINDER Study. Presented by Tejaswini Kulkarni, M.D., MPH, FCCP, University of Alabama at Birmingham.

Rapid fire original investigation presentation, Tuesday, October 21, 2:03 p.m. to 2:07 p.m. CDT: Rapid Area 3D/4073 – Impact of Inhaled Treprostinil Initiation Timing on Hospitalizations in Patients with PH-ILD. Presented by Karim El-Kersh, M.D., University of Arizona.

Sponsored and hosted events include:

The 2025 Pulmonary and Critical Care Medicine Fellows Breakfast, Saturday, October 18, 6:15 a.m to 7:15 a.m. CDT. This session will be a case-based session addressing the complex disease state of interstitial lung disease and pulmonary hypertension.

The Women in Chest Medicine Annual Luncheon, Monday, October 20, 12:00 p.m. to 1:30 p.m. CDT.

Cheers and Challenges: Game On! (for APPs), Monday, October 20, 5:30 p.m. to 7:00 p.m. CDT. Join fellow advanced practice providers for an evening of friendly competition and connection.

PHinding Pulmonary Hypertension: Exploring Best Practices in PH-ILD Detection and Management, Monday, October 20, 6:00 p.m. to 9:00 p.m. CDT.

United Therapeutics: Enabling Inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

You can learn more about what it means to be a PBC here: unither.com/pbc.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding anticipated presentations and other events at the upcoming CHEST Annual Meeting, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 13, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.